# 靶点初评报告  (verdict: PASS)

## Genetic evidence
TP53 shows strong genetic associations with cancer predisposition (e.g., Li-Fraumeni syndrome, OR=8.4, p=3.1e-42) and specific cancers like breast cancer (OR=1.6, p=2.7e-18) and lung adenocarcinoma (OR=1.9, p=9.4e-12), but no significant association with coronary artery disease (CAD) (OR=1.02, p=0.42) [from query_gwas_data].

## Expression & on-/off-target rationale
TP53 exhibits low expression in heart tissue (TPM=2.1) and is primarily enriched in tumor microenvironments (TPM=86.3) and immune cells (TPM=24.8), with moderate expression in liver (TPM=11.7) [from query_expression_atlas]. This low cardiac expression suggests limited physiological role in normal heart function, reducing on-target relevance for cardiovascular modulation.

## Prior-art & druggability
Direct pharmacological targeting of TP53 remains highly challenging despite decades of research; no clinically approved agents restore wild-type TP53 function, and current efforts focus on mutant TP53 reactivators (e.g., APR-246) [from search_pubmed_literature]. TP53 is generally considered a poor cardiovascular target due to lack of tissue rationale and high oncogenic risk from off-target activation [from search_pubmed_literature].

## Overall verdict (risk / feasibility)
High risk, low feasibility. TP53 lacks genetic support for cardiovascular involvement, exhibits minimal expression in heart tissue, and remains undruggable via direct targeting. Modulating TP53 in cardiovascular contexts would likely induce severe off-target oncogenic risks due to its central tumor-suppressor role, with no established therapeutic mechanism. [inference from query_gwas_data, query_expression_atlas, search_pubmed_literature]

---
*Verdict reason:* No open issues after Reviewer grounding.
